BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel intervention strategy for the prevention HIV transmission. Because several clinical trials are at various stages of completion, it is important to understand the impact of PrEP treatment on the development of the immune response to HIV, particularly in individuals who exhibit breakthrough infections despite PrEP. METHODS: A model of HIV infection, using rhesus macaques and the simian/human immunodeficiency virus (SHIV), was used to evaluate the effects of PrEP on the evolution of the humoral immune response. Time to seroconversion, neutralizing and binding antibody levels, and antibody avidity were measured in 12 rhesus macaques infected during daily or intermittent PrEP with FTC (emtricitabine) or Truvada (FTC/tenofovir combination) and compared with 11 untreated, simian HIV-infected controls. RESULTS: Macaques that became infected while receiving PrEP exhibited significantly lower peak virus loads during acute infection as compared with untreated animals. Although the timing of seroconversion and SHIV binding and neutralizing antibody levels were not impacted by treatment, lower maturation rates of antibody avidity for anti-p27, gp120, gp160, and gp41 were observed. CONCLUSIONS: This study suggests that reduced virus loads associated with PrEP treatment have little impact on timing of seroconversion and neutralizing/binding antibody levels; however, maturation of antibody avidity was suppressed.
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel intervention strategy for the prevention HIV transmission. Because several clinical trials are at various stages of completion, it is important to understand the impact of PrEP treatment on the development of the immune response to HIV, particularly in individuals who exhibit breakthrough infections despite PrEP. METHODS: A model of HIV infection, using rhesus macaques and the simian/human immunodeficiency virus (SHIV), was used to evaluate the effects of PrEP on the evolution of the humoral immune response. Time to seroconversion, neutralizing and binding antibody levels, and antibody avidity were measured in 12 rhesus macaques infected during daily or intermittent PrEP with FTC (emtricitabine) or Truvada (FTC/tenofovir combination) and compared with 11 untreated, simian HIV-infected controls. RESULTS: Macaques that became infected while receiving PrEP exhibited significantly lower peak virus loads during acute infection as compared with untreated animals. Although the timing of seroconversion and SHIV binding and neutralizing antibody levels were not impacted by treatment, lower maturation rates of antibody avidity for anti-p27, gp120, gp160, and gp41 were observed. CONCLUSIONS: This study suggests that reduced virus loads associated with PrEP treatment have little impact on timing of seroconversion and neutralizing/binding antibody levels; however, maturation of antibody avidity was suppressed.
Authors: Marina R Alexander; Rajesh Ringe; Rogier W Sanders; James E Voss; John P Moore; Per Johan Klasse Journal: J Virol Date: 2015-03-25 Impact factor: 5.103
Authors: Mariya V Sivay; Maoji Li; Estelle Piwowar-Manning; Yinfeng Zhang; Sarah E Hudelson; Mark A Marzinke; Rivet K Amico; Andrew Redd; Craig W Hendrix; Peter L Anderson; Kevin Bokoch; Linda-Gail Bekker; Frits van Griensven; Sharon Mannheimer; James P Hughes; Robert Grant; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.731
Authors: Oliver Laeyendecker; Andrew D Redd; Martha Nason; Andrew F Longosz; Quarraisha Abdool Karim; Vivek Naranbhai; Nigel Garrett; Susan H Eshleman; Salim S Abdool Karim; Thomas C Quinn Journal: J Infect Dis Date: 2015-02-23 Impact factor: 5.226
Authors: Ted M Ross; Lara E Pereira; Amara Luckay; Janet M McNicholl; J Gerardo García-Lerma; Walid Heneine; Hermancia S Eugene; Brooke R Pierce-Paul; Jining Zhang; R Michael Hendry; James M Smith Journal: AIDS Res Hum Retroviruses Date: 2014-07-29 Impact factor: 2.205
Authors: Ivana Parker; George Khalil; Amy Martin; Michael Martin; Suphak Vanichseni; Wanna Leelawiwat; Janet McNicholl; Andrew Hickey; J Gerardo García-Lerma; Kachit Choopanya; Kelly A Curtis Journal: AIDS Res Hum Retroviruses Date: 2020-12-09 Impact factor: 2.205